CN104703991B - 黄病毒科病毒的大环抑制剂 - Google Patents
黄病毒科病毒的大环抑制剂 Download PDFInfo
- Publication number
- CN104703991B CN104703991B CN201380039194.XA CN201380039194A CN104703991B CN 104703991 B CN104703991 B CN 104703991B CN 201380039194 A CN201380039194 A CN 201380039194A CN 104703991 B CN104703991 B CN 104703991B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- mmol
- compound
- ethyl acetate
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCC(C)C[C@@](C*C(C)*)C=C1C(C)CC2C1C2 Chemical compound CCC(C)C[C@@](C*C(C)*)C=C1C(C)CC2C1C2 0.000 description 79
- AYBZKCHWOBOGHM-UHFFFAOYSA-N CC(C(CC=C)CC1)N=C1C(C)(C)C Chemical compound CC(C(CC=C)CC1)N=C1C(C)(C)C AYBZKCHWOBOGHM-UHFFFAOYSA-N 0.000 description 1
- CRXMCEGXLSUJFN-OHADLKNJSA-N CC(C(N(CCC1)N[C@@H]1C(O)=O)=O)NC([C@H](Cc1ccccc1)NC(C/C=C/C)=O)=O Chemical compound CC(C(N(CCC1)N[C@@H]1C(O)=O)=O)NC([C@H](Cc1ccccc1)NC(C/C=C/C)=O)=O CRXMCEGXLSUJFN-OHADLKNJSA-N 0.000 description 1
- HBEWZKNFIPQRCZ-PZORYLMUSA-N CC(C(OC)=O)Oc(cc1)ccc1-c1cc([C@@H](C)O)ccc1 Chemical compound CC(C(OC)=O)Oc(cc1)ccc1-c1cc([C@@H](C)O)ccc1 HBEWZKNFIPQRCZ-PZORYLMUSA-N 0.000 description 1
- OIPOWPNOZBLYLW-UHFFFAOYSA-N CC(C)(C(OC)=O)c1cccc(B2OC(C)(C)C(C)(C)O2)c1 Chemical compound CC(C)(C(OC)=O)c1cccc(B2OC(C)(C)C(C)(C)O2)c1 OIPOWPNOZBLYLW-UHFFFAOYSA-N 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N CC(C)(C)OC(N)=O Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- RQXUDOCAWHFOMD-QMMMGPOBSA-N CC(C)(C)[S@@](NC)=O Chemical compound CC(C)(C)[S@@](NC)=O RQXUDOCAWHFOMD-QMMMGPOBSA-N 0.000 description 1
- IWAYEGDLFBCGBD-UHFFFAOYSA-N CC(C)(C)[U]C(CC(C(O)=O)NC(OCC1c(cccc2)c2-c2c1cccc2)=N)=O Chemical compound CC(C)(C)[U]C(CC(C(O)=O)NC(OCC1c(cccc2)c2-c2c1cccc2)=N)=O IWAYEGDLFBCGBD-UHFFFAOYSA-N 0.000 description 1
- YXGXINHDVMLPCY-UHFFFAOYSA-N CC(C)(C)[U]C(N(C)C)=O Chemical compound CC(C)(C)[U]C(N(C)C)=O YXGXINHDVMLPCY-UHFFFAOYSA-N 0.000 description 1
- MGYXTJUZTDNIBO-UHFFFAOYSA-N CC(C)C(CNC(OC(C)(C)C)=O)C(NC(C)C(N(CCC1)NC1C(OC)=O)=O)=O Chemical compound CC(C)C(CNC(OC(C)(C)C)=O)C(NC(C)C(N(CCC1)NC1C(OC)=O)=O)=O MGYXTJUZTDNIBO-UHFFFAOYSA-N 0.000 description 1
- NEELSHGBEWJUAV-UJOGXGMISA-N CC(C)[C@@H](C(NC(C(N(CCC1)N[C@@H]1C(O[C@H](C)c1nc2cc(/C=C/C3(CC4)CCN4S(C)(=O)=O)ccc2cc1)=O)=O)=C)=O)NC3=O Chemical compound CC(C)[C@@H](C(NC(C(N(CCC1)N[C@@H]1C(O[C@H](C)c1nc2cc(/C=C/C3(CC4)CCN4S(C)(=O)=O)ccc2cc1)=O)=O)=C)=O)NC3=O NEELSHGBEWJUAV-UJOGXGMISA-N 0.000 description 1
- AXJLUFUIYKMWII-MLWJPKLSSA-N CC(C)[C@@H](C(NC(C)C=O)=O)N Chemical compound CC(C)[C@@H](C(NC(C)C=O)=O)N AXJLUFUIYKMWII-MLWJPKLSSA-N 0.000 description 1
- CCIQRGJBZGLKHU-NKSUYOJZSA-O CC(C)[C@@H](C(NC[C@@H](COC)C(N(CCCC1)N[C@@H]1C(OCC(Cl)(Cl)Cl)=O)[OH2+])=O)NC(COC(C)(C)C)=C Chemical compound CC(C)[C@@H](C(NC[C@@H](COC)C(N(CCCC1)N[C@@H]1C(OCC(Cl)(Cl)Cl)=O)[OH2+])=O)NC(COC(C)(C)C)=C CCIQRGJBZGLKHU-NKSUYOJZSA-O 0.000 description 1
- ORPGVNYLRRLPDS-SPOFRUOTSA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)NC1C(OCC(Cl)(Cl)Cl)=O)=O)=N)NC(C(C)(C)/C=C/c1cc(nc([C@@H](C)OC(C)=O)cc2)c2cc1)=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)NC1C(OCC(Cl)(Cl)Cl)=O)=O)=N)NC(C(C)(C)/C=C/c1cc(nc([C@@H](C)OC(C)=O)cc2)c2cc1)=O ORPGVNYLRRLPDS-SPOFRUOTSA-N 0.000 description 1
- DEUOXJPXCHKGNF-PRXCNWMYSA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1/C(/N(CCC1)[C@@H]1c1ccc(ccc(/C=C/C2(C)C)c3)c3n1)=[O]\CC(C)(/C=C/c1ccc(ccc([C@@H](CCC3)N3C([C@H](CCC3)NN3C([C@H](C)NC(C(C(C)C)N3)=O)=O)=O)n4)c4c1)C3=O)=O)=O)NC2=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1/C(/N(CCC1)[C@@H]1c1ccc(ccc(/C=C/C2(C)C)c3)c3n1)=[O]\CC(C)(/C=C/c1ccc(ccc([C@@H](CCC3)N3C([C@H](CCC3)NN3C([C@H](C)NC(C(C(C)C)N3)=O)=O)=O)n4)c4c1)C3=O)=O)=O)NC2=O DEUOXJPXCHKGNF-PRXCNWMYSA-N 0.000 description 1
- LURLDFUOIKEELM-NPKGIASISA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c(cc1)nc2c1ccc(/C=C/CCC(CC1)(F)F)c2)=O)=O)=O)NC1=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c(cc1)nc2c1ccc(/C=C/CCC(CC1)(F)F)c2)=O)=O)=O)NC1=O LURLDFUOIKEELM-NPKGIASISA-N 0.000 description 1
- KATAXUKVLLQRKG-BQFCYCMXSA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(O)=O)=O)=N)NC(CCC(C)(C)CC=C)=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(O)=O)=O)=N)NC(CCC(C)(C)CC=C)=O KATAXUKVLLQRKG-BQFCYCMXSA-N 0.000 description 1
- ZFSJGBXEVGSOSI-YENCOAQQSA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(O[C@H](C)c1nc(cc(cc2)/C=C/C3(C)C)c2c(Br)c1)=O)=O)=O)NC3=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(O[C@H](C)c1nc(cc(cc2)/C=C/C3(C)C)c2c(Br)c1)=O)=O)=O)NC3=O ZFSJGBXEVGSOSI-YENCOAQQSA-N 0.000 description 1
- KDCKRHBGWDHYQJ-JRUYECLLSA-O CC(C)[C@H](C)C(NC(C)C(N(CCC1)N[C@@H]1C([OH2+])=O)=O)=O Chemical compound CC(C)[C@H](C)C(NC(C)C(N(CCC1)N[C@@H]1C([OH2+])=O)=O)=O KDCKRHBGWDHYQJ-JRUYECLLSA-O 0.000 description 1
- PYCIICCNKRZBJO-WVTMANGGSA-N CC(C)[C@H](CO1)N(C([C@](C)(CCc(cc2)cc3c2ccc([C@@H](C)OC(C)=O)n3)COC)=O)C1=N Chemical compound CC(C)[C@H](CO1)N(C([C@](C)(CCc(cc2)cc3c2ccc([C@@H](C)OC(C)=O)n3)COC)=O)C1=N PYCIICCNKRZBJO-WVTMANGGSA-N 0.000 description 1
- FXIDUMFAIRDUGT-NYMKFKOJSA-N CC(CC([U]C(C)(C)C)=O)C(N(CCC1)N[C@@H]1C(OCC(C)(Cl)Cl)=O)=O Chemical compound CC(CC([U]C(C)(C)C)=O)C(N(CCC1)N[C@@H]1C(OCC(C)(Cl)Cl)=O)=O FXIDUMFAIRDUGT-NYMKFKOJSA-N 0.000 description 1
- OOYNHRHZUXAHSV-UHFFFAOYSA-N CC(CCO1)(C=C)C1=O Chemical compound CC(CCO1)(C=C)C1=O OOYNHRHZUXAHSV-UHFFFAOYSA-N 0.000 description 1
- QGLBZNZGBLRJGS-UHFFFAOYSA-N CC(CCO1)C1=O Chemical compound CC(CCO1)C1=O QGLBZNZGBLRJGS-UHFFFAOYSA-N 0.000 description 1
- PLFQHVVOXUDKCP-RRKGBCIJSA-N CC(CO[C@H](C)c(cc1)nc2c1C=CC=CC(Br)=C2F)O Chemical compound CC(CO[C@H](C)c(cc1)nc2c1C=CC=CC(Br)=C2F)O PLFQHVVOXUDKCP-RRKGBCIJSA-N 0.000 description 1
- WQPQOGFTGJBJDU-UHFFFAOYSA-N CC(N)[ClH]C(C)(C)C Chemical compound CC(N)[ClH]C(C)(C)C WQPQOGFTGJBJDU-UHFFFAOYSA-N 0.000 description 1
- VMNRNPLQHDOTCL-UHFFFAOYSA-N CC(c1ccc(C)c(Br)c1)NC(OC(C)(C)C)=[O]=C Chemical compound CC(c1ccc(C)c(Br)c1)NC(OC(C)(C)C)=[O]=C VMNRNPLQHDOTCL-UHFFFAOYSA-N 0.000 description 1
- QPRDNXRAPOOMJH-UHFFFAOYSA-N CC1C(c2c(C3COC(N)=O)cccc2)=C3C=CC1 Chemical compound CC1C(c2c(C3COC(N)=O)cccc2)=C3C=CC1 QPRDNXRAPOOMJH-UHFFFAOYSA-N 0.000 description 1
- CLFGXPBRMNXTGQ-SLTAFYQDSA-N CC1NN(CC(C(N(CCC2)N[C@@H]2C(OCC(C)(Cl)Cl)=O)=O)NC(OC(C)(C)C)=O)C=C1 Chemical compound CC1NN(CC(C(N(CCC2)N[C@@H]2C(OCC(C)(Cl)Cl)=O)=O)NC(OC(C)(C)C)=O)C=C1 CLFGXPBRMNXTGQ-SLTAFYQDSA-N 0.000 description 1
- WGMLAYWUIRWZPG-UHFFFAOYSA-N CCC(C)CN[IH]C Chemical compound CCC(C)CN[IH]C WGMLAYWUIRWZPG-UHFFFAOYSA-N 0.000 description 1
- JTPFMPBLMXKTFY-UHFFFAOYSA-N CCC1C2NCCC12 Chemical compound CCC1C2NCCC12 JTPFMPBLMXKTFY-UHFFFAOYSA-N 0.000 description 1
- VPFYWIUCYZAGNM-QFWMXSHPSA-N CCC[C@@H](C)[IH]CC(CC(CF)F)C1CC1 Chemical compound CCC[C@@H](C)[IH]CC(CC(CF)F)C1CC1 VPFYWIUCYZAGNM-QFWMXSHPSA-N 0.000 description 1
- SGNJUBQJZFPEME-PKEIRNPWSA-N CCc(cc1)cc2c1C=CC([C@@H](C)O)N2 Chemical compound CCc(cc1)cc2c1C=CC([C@@H](C)O)N2 SGNJUBQJZFPEME-PKEIRNPWSA-N 0.000 description 1
- ADDRWLKXMLYTLN-UHFFFAOYSA-N CCc(cc1)cc2c1cnc(-c1cccc(C(C)(C)C(OC)=O)c1)c2 Chemical compound CCc(cc1)cc2c1cnc(-c1cccc(C(C)(C)C(OC)=O)c1)c2 ADDRWLKXMLYTLN-UHFFFAOYSA-N 0.000 description 1
- MPTORJNRYFFRHD-DJYYSNQPSA-N CCc(cc1)nc2c1ccc(/C=C/[C@H]([C@H](C)O)C(N[C@@H](C(C)C)C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(O)=O)=O)=O)=O)c2 Chemical compound CCc(cc1)nc2c1ccc(/C=C/[C@H]([C@H](C)O)C(N[C@@H](C(C)C)C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(O)=O)=O)=O)=O)c2 MPTORJNRYFFRHD-DJYYSNQPSA-N 0.000 description 1
- VMOGBOBURVTQOJ-SNVBAGLBSA-N CN[C@H](CC1)c2c1ccc(Br)c2 Chemical compound CN[C@H](CC1)c2c1ccc(Br)c2 VMOGBOBURVTQOJ-SNVBAGLBSA-N 0.000 description 1
- KTUOZGFOBZFEGT-UHFFFAOYSA-N COC(C1(CCCC1)C=C)=O Chemical compound COC(C1(CCCC1)C=C)=O KTUOZGFOBZFEGT-UHFFFAOYSA-N 0.000 description 1
- ZWYOBCBPOGJGOK-UHFFFAOYSA-N COC(C1(CCOCC1)C#C)=O Chemical compound COC(C1(CCOCC1)C#C)=O ZWYOBCBPOGJGOK-UHFFFAOYSA-N 0.000 description 1
- ZDAZIHHIAHBVFL-QDKLYSGJSA-N C[C@@H](/C=C/C)C(N([C@H](Cc1ccccc1)CO1)C1=O)=O Chemical compound C[C@@H](/C=C/C)C(N([C@H](Cc1ccccc1)CO1)C1=O)=O ZDAZIHHIAHBVFL-QDKLYSGJSA-N 0.000 description 1
- XTPHQNSNOUJMID-AIVWGNJPSA-N C[C@@H](C(N(CCC1)N[C@@H]1C([U]CC(Cl)(Cl)Cl)=O)=O)NC([C@H](C1CCCCC1)NC(C/C=C/C)=O)=O Chemical compound C[C@@H](C(N(CCC1)N[C@@H]1C([U]CC(Cl)(Cl)Cl)=O)=O)NC([C@H](C1CCCCC1)NC(C/C=C/C)=O)=O XTPHQNSNOUJMID-AIVWGNJPSA-N 0.000 description 1
- LLXXADIECONBNJ-SSDOTTSWSA-N C[C@H](C(CC1)=Cc2c1cnc(Cl)c2)N Chemical compound C[C@H](C(CC1)=Cc2c1cnc(Cl)c2)N LLXXADIECONBNJ-SSDOTTSWSA-N 0.000 description 1
- RFMVGCXENCIUOI-LKSINWNRSA-N C[C@H](C(CC=C1)C=C1c(cc1)ccc1OC(C)C(O)=O)O Chemical compound C[C@H](C(CC=C1)C=C1c(cc1)ccc1OC(C)C(O)=O)O RFMVGCXENCIUOI-LKSINWNRSA-N 0.000 description 1
- RLQWDBYWUVEVDC-IPXPQQMRSA-N C[C@H](C1N=C(C=C(/C=C/[C@](C)(/C=[O]/C)C(O)=O)C=C2)C2=C[C@H]1C)O Chemical compound C[C@H](C1N=C(C=C(/C=C/[C@](C)(/C=[O]/C)C(O)=O)C=C2)C2=C[C@H]1C)O RLQWDBYWUVEVDC-IPXPQQMRSA-N 0.000 description 1
- IWFJLMINJLESDE-PBQZMEPESA-N C[C@H](c(cc1)nc2c1ccc(/C=C/C(C)(C)C(O)=O)c2F)OC(C)=O Chemical compound C[C@H](c(cc1)nc2c1ccc(/C=C/C(C)(C)C(O)=O)c2F)OC(C)=O IWFJLMINJLESDE-PBQZMEPESA-N 0.000 description 1
- NTKPHNSGZVTRJG-MVIFTORASA-N C[C@H](c1cc(cc(/C=C/C(C)(C)C(OC)=O)nc2)c2nc1)O Chemical compound C[C@H](c1cc(cc(/C=C/C(C)(C)C(OC)=O)nc2)c2nc1)O NTKPHNSGZVTRJG-MVIFTORASA-N 0.000 description 1
- WHAFLPMAEHDLTP-SSDOTTSWSA-N C[C@H](c1cc2cc(Cl)ncc2cc1)O Chemical compound C[C@H](c1cc2cc(Cl)ncc2cc1)O WHAFLPMAEHDLTP-SSDOTTSWSA-N 0.000 description 1
- WZWPGKHAUJNYEJ-MRVPVSSYSA-N C[C@H](c1ccc(ccc([Br]=C)c2)c2n1)O Chemical compound C[C@H](c1ccc(ccc([Br]=C)c2)c2n1)O WZWPGKHAUJNYEJ-MRVPVSSYSA-N 0.000 description 1
- CFOBSDCPKRFCEZ-IYPOZPNPSA-N C[C@H](c1cccc(-c2ncc(/C=C/C(OCCc3ccccc3)=O)cc2)c1)O Chemical compound C[C@H](c1cccc(-c2ncc(/C=C/C(OCCc3ccccc3)=O)cc2)c1)O CFOBSDCPKRFCEZ-IYPOZPNPSA-N 0.000 description 1
- MTKYYURQKQCBCN-MRVPVSSYSA-N C[C@H](c1nc2cc(Br)ccc2cc1)OC(C)=O Chemical compound C[C@H](c1nc2cc(Br)ccc2cc1)OC(C)=O MTKYYURQKQCBCN-MRVPVSSYSA-N 0.000 description 1
- RBGYJJBGYGBURD-RWEWTDSWSA-N O=C(C(OCCCOC(c1cc(cc(cc2)Br)c2nn1)=O)=O)/N=N\c(cc1)ccc1Br Chemical compound O=C(C(OCCCOC(c1cc(cc(cc2)Br)c2nn1)=O)=O)/N=N\c(cc1)ccc1Br RBGYJJBGYGBURD-RWEWTDSWSA-N 0.000 description 1
- UAIXKTHHPYZVGG-YFKPBYRVSA-N O=C([C@H]1NNCCC1)OCC(Cl)(Cl)Cl Chemical compound O=C([C@H]1NNCCC1)OCC(Cl)(Cl)Cl UAIXKTHHPYZVGG-YFKPBYRVSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657550P | 2012-06-08 | 2012-06-08 | |
| US61/657,550 | 2012-06-08 | ||
| PCT/US2013/044826 WO2013185103A1 (en) | 2012-06-08 | 2013-06-07 | Macrocyclic inhibitors of flaviviridae viruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104703991A CN104703991A (zh) | 2015-06-10 |
| CN104703991B true CN104703991B (zh) | 2018-03-23 |
Family
ID=48692655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380039194.XA Expired - Fee Related CN104703991B (zh) | 2012-06-08 | 2013-06-07 | 黄病毒科病毒的大环抑制剂 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9145441B2 (https=) |
| EP (1) | EP2861604B1 (https=) |
| JP (1) | JP6209601B2 (https=) |
| KR (1) | KR20150040265A (https=) |
| CN (1) | CN104703991B (https=) |
| AU (1) | AU2013270672B2 (https=) |
| BR (1) | BR112014030630A2 (https=) |
| CA (1) | CA2875692A1 (https=) |
| EA (1) | EA026235B1 (https=) |
| ES (1) | ES2624223T3 (https=) |
| HK (1) | HK1211285A1 (https=) |
| IL (1) | IL236005A0 (https=) |
| IN (1) | IN2014MN02652A (https=) |
| MX (1) | MX2014014766A (https=) |
| NZ (2) | NZ724503A (https=) |
| PL (1) | PL2861604T3 (https=) |
| PT (1) | PT2861604T (https=) |
| SG (1) | SG11201408047XA (https=) |
| SI (1) | SI2861604T1 (https=) |
| WO (1) | WO2013185103A1 (https=) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR091279A1 (es) * | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| PT2861604T (pt) | 2012-06-08 | 2017-05-05 | Gilead Sciences Inc | Inibidores macrocíclicos de vírus flaviridae |
| BR112014030649A2 (pt) | 2012-06-08 | 2017-06-27 | Gilead Sciences Inc | inibidores macrocíclicos da flaviviridae vírus |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| US9670205B2 (en) | 2015-03-04 | 2017-06-06 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| WO2017007892A1 (en) * | 2015-07-07 | 2017-01-12 | Nch Corporation | System and method for treating water with a biological based biocide |
| US20210292327A1 (en) | 2015-08-26 | 2021-09-23 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| EA201892375A1 (ru) | 2016-05-27 | 2019-08-30 | Джилид Сайэнс, Инк. | Способы лечения инфекций, вызываемых вирусом гепатита b |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| US10961213B2 (en) | 2017-01-25 | 2021-03-30 | Basf Se | Process for preparation of benzylic amides |
| TW202510891A (zh) | 2017-01-31 | 2025-03-16 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| UY37581A (es) | 2017-02-02 | 2018-08-31 | Gilead Sciences Inc | Compuestos para el tratamiento de la infección por virus de la hepatitis b |
| WO2018172250A1 (en) | 2017-03-21 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN109384727B (zh) * | 2017-08-10 | 2023-07-28 | 中国科学院上海药物研究所 | 酞嗪酮类化合物、其制备方法、药物组合物及用途 |
| CN111051305A (zh) | 2017-08-22 | 2020-04-21 | 吉利德科学公司 | 治疗性杂环化合物 |
| PT3706762T (pt) | 2017-12-07 | 2024-12-05 | Univ Emory | N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos |
| SMT202200396T1 (it) | 2017-12-13 | 2022-11-18 | Lupin Ltd | Composti eterociclici biciclici sostituiti come inibitori di prmt5 |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| US20220274979A1 (en) | 2018-04-18 | 2022-09-01 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| US11186579B2 (en) | 2018-07-06 | 2021-11-30 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| AU2019297362B2 (en) | 2018-07-06 | 2022-05-26 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| DK4037708T3 (da) | 2019-09-30 | 2024-09-30 | Gilead Sciences Inc | HBV-vacciner og fremgangsmåder til at behandle HBV |
| AU2020377925A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| IL322454A (en) * | 2019-11-04 | 2025-09-01 | Revolution Medicines Inc | ras inhibitors |
| TW202132316A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| WO2021198981A1 (en) | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Antiviral compounds and uses thereof |
| EP4192474B1 (en) | 2020-08-07 | 2025-09-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| US20230357239A1 (en) | 2020-09-18 | 2023-11-09 | Bayer Aktiengesellschaft | Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| KR20240017811A (ko) | 2021-05-05 | 2024-02-08 | 레볼루션 메디슨즈, 인크. | 암의 치료를 위한 ras 억제제 |
| WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN114634421A (zh) * | 2022-02-24 | 2022-06-17 | 济宁晟泰药业有限公司 | 一种达沙替尼中间体的制备方法 |
| MA71611A (fr) | 2022-07-29 | 2025-05-30 | Pfizer Inc. | Nouveaux inhibiteurs de l'acc |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006138507A1 (en) * | 2005-06-17 | 2006-12-28 | Novartis Ag | Use of sanglifehrin in hcv |
| WO2011088345A1 (en) * | 2010-01-15 | 2011-07-21 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
| WO2011098808A1 (en) * | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| WO2011144924A1 (en) * | 2010-05-17 | 2011-11-24 | Biotica Technology Limited | Amine or amid analogues of sanglifehrin |
| WO2012040040A1 (en) * | 2010-09-21 | 2012-03-29 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| WO2012078915A1 (en) * | 2010-12-10 | 2012-06-14 | Gilead Sciences, Inc. | Macrocyclic inhibitors of flaviviridae viruses |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR006514A1 (es) | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| US20050159345A1 (en) | 2002-10-29 | 2005-07-21 | Boehringer Ingelheim International Gmbh | Composition for the treatment of infection by Flaviviridae viruses |
| NZ564326A (en) | 2005-06-16 | 2010-01-29 | Cv Therapeutics Inc | Prodrugs of A2B adenosine receptor antagonists |
| EP2011786A1 (en) | 2007-07-05 | 2009-01-07 | Laboratorios del Dr. Esteve S.A. | Indane-amine derivatives, their preparation and use as medicaments |
| CL2008003384A1 (es) * | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| WO2009088256A2 (ko) | 2008-01-09 | 2009-07-16 | Konkuk University Industrial Cooperation Corp | 배큘로바이러스-기반 백신 |
| US20100080770A1 (en) * | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| SI2382198T1 (sl) * | 2008-12-23 | 2013-11-29 | Janssen Pharmaceuticals, Inc. | Postopek in vmesne spojine za pripravo makrocikličnega inhibitorja HCV proteaze |
| WO2011063233A1 (en) | 2009-11-23 | 2011-05-26 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| EP2525659B1 (en) | 2010-01-19 | 2019-02-27 | Merck Sharp & Dohme Corp. | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS |
| AR091279A1 (es) * | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| BR112014030649A2 (pt) | 2012-06-08 | 2017-06-27 | Gilead Sciences Inc | inibidores macrocíclicos da flaviviridae vírus |
| PT2861604T (pt) | 2012-06-08 | 2017-05-05 | Gilead Sciences Inc | Inibidores macrocíclicos de vírus flaviridae |
| SG11201408093PA (en) | 2012-06-08 | 2015-01-29 | Glenmark Pharmaceuticals Sa | Amides of 2-amino-4-arylthiazole compounds and their salts |
-
2013
- 2013-06-07 PT PT137312039T patent/PT2861604T/pt unknown
- 2013-06-07 US US13/913,259 patent/US9145441B2/en not_active Ceased
- 2013-06-07 PL PL13731203T patent/PL2861604T3/pl unknown
- 2013-06-07 SG SG11201408047XA patent/SG11201408047XA/en unknown
- 2013-06-07 WO PCT/US2013/044826 patent/WO2013185103A1/en not_active Ceased
- 2013-06-07 CN CN201380039194.XA patent/CN104703991B/zh not_active Expired - Fee Related
- 2013-06-07 CA CA2875692A patent/CA2875692A1/en not_active Abandoned
- 2013-06-07 MX MX2014014766A patent/MX2014014766A/es unknown
- 2013-06-07 HK HK15111999.1A patent/HK1211285A1/xx unknown
- 2013-06-07 ES ES13731203.9T patent/ES2624223T3/es active Active
- 2013-06-07 IN IN2652MUN2014 patent/IN2014MN02652A/en unknown
- 2013-06-07 NZ NZ724503A patent/NZ724503A/en not_active IP Right Cessation
- 2013-06-07 KR KR1020157000171A patent/KR20150040265A/ko not_active Withdrawn
- 2013-06-07 EP EP13731203.9A patent/EP2861604B1/en not_active Not-in-force
- 2013-06-07 BR BR112014030630A patent/BR112014030630A2/pt not_active Application Discontinuation
- 2013-06-07 NZ NZ703040A patent/NZ703040A/en not_active IP Right Cessation
- 2013-06-07 SI SI201330574A patent/SI2861604T1/sl unknown
- 2013-06-07 JP JP2015516260A patent/JP6209601B2/ja not_active Expired - Fee Related
- 2013-06-07 AU AU2013270672A patent/AU2013270672B2/en not_active Ceased
- 2013-06-07 EA EA201492209A patent/EA026235B1/ru not_active IP Right Cessation
-
2014
- 2014-11-30 IL IL236005A patent/IL236005A0/en unknown
-
2015
- 2015-08-07 US US14/821,458 patent/US9512175B2/en not_active Expired - Fee Related
-
2017
- 2017-09-25 US US15/715,080 patent/USRE47334E1/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006138507A1 (en) * | 2005-06-17 | 2006-12-28 | Novartis Ag | Use of sanglifehrin in hcv |
| WO2011088345A1 (en) * | 2010-01-15 | 2011-07-21 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
| WO2011098808A1 (en) * | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| WO2011144924A1 (en) * | 2010-05-17 | 2011-11-24 | Biotica Technology Limited | Amine or amid analogues of sanglifehrin |
| WO2012040040A1 (en) * | 2010-09-21 | 2012-03-29 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| WO2012078915A1 (en) * | 2010-12-10 | 2012-06-14 | Gilead Sciences, Inc. | Macrocyclic inhibitors of flaviviridae viruses |
Also Published As
| Publication number | Publication date |
|---|---|
| NZ724503A (en) | 2017-12-22 |
| MX2014014766A (es) | 2015-05-11 |
| JP2015518904A (ja) | 2015-07-06 |
| IL236005A0 (en) | 2015-02-01 |
| CN104703991A (zh) | 2015-06-10 |
| EP2861604A1 (en) | 2015-04-22 |
| IN2014MN02652A (https=) | 2015-08-21 |
| ES2624223T3 (es) | 2017-07-13 |
| US9512175B2 (en) | 2016-12-06 |
| JP6209601B2 (ja) | 2017-10-04 |
| KR20150040265A (ko) | 2015-04-14 |
| HK1209730A1 (en) | 2016-04-08 |
| US20140030221A1 (en) | 2014-01-30 |
| PL2861604T3 (pl) | 2017-08-31 |
| BR112014030630A2 (pt) | 2017-06-27 |
| SG11201408047XA (en) | 2015-01-29 |
| AU2013270672A1 (en) | 2015-01-22 |
| US20150344521A1 (en) | 2015-12-03 |
| PT2861604T (pt) | 2017-05-05 |
| EP2861604B1 (en) | 2017-03-01 |
| NZ703040A (en) | 2016-11-25 |
| EA201492209A1 (ru) | 2015-05-29 |
| CA2875692A1 (en) | 2013-12-12 |
| EA026235B1 (ru) | 2017-03-31 |
| USRE47334E1 (en) | 2019-04-02 |
| SI2861604T1 (sl) | 2017-05-31 |
| AU2013270672B2 (en) | 2017-10-19 |
| US9145441B2 (en) | 2015-09-29 |
| WO2013185103A1 (en) | 2013-12-12 |
| HK1211285A1 (en) | 2016-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104703991B (zh) | 黄病毒科病毒的大环抑制剂 | |
| CN104662033B (zh) | 黄病毒科病毒的大环抑制剂 | |
| CN104781261B (zh) | 黄病毒科病毒的大环抑制剂 | |
| TWI610916B (zh) | 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用 | |
| CN103403009A (zh) | 黄病毒科病毒的大环抑制剂 | |
| HK1212349B (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| HK1209730B (en) | Macrocyclic inhibitors of flaviviridae viruses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1211285 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180629 Address after: American California Co-patentee after: This company limited in western pula Patentee after: Gilead Sciences Inc. Address before: Forster, California, 94404 Co-patentee before: Selcia Ltd. Patentee before: Gilead Sciences Inc. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180323 Termination date: 20190607 |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1211285 Country of ref document: HK |